Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 116 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Daclatasvir. Prescrire 2015;35:738-9. [Ref.ID 99846]
2. Cita con resumen
Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]
3.Enlace a cita original Cita con resumen
Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]
4. Cita con resumen
Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-6. [Ref.ID 99556]
5. Cita con resumen
Anónimo. Peginterferon beta-1a (Plegridy) for multiple sclerosis. Med Lett Drugs Ther 2015;57:67-9. [Ref.ID 99450]
6. Cita con resumen
Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]
7. Cita con resumen
Anónimo. Siméprévir. Prescrire 2015;35:94-5. [Ref.ID 98910]
8. Cita con resumen
Lawitz E, Sulkowski MS, Ghalib R, Rodríguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkek-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65. [Ref.ID 98325]
9. Cita con resumen
Liang TJ, Ghany MG. Therapy of hepatitis C. Back to the future. N Engl J Med 2014;370:2043-7. [Ref.ID 97487]
10.Tiene citas relacionadas Cita con resumen
Hoofnagle JH, Sherker AH. Therapy for hepatitis C - the costs of success. N Engl J Med 2014;370:1552-3. [Ref.ID 97486]
11.Tiene citas relacionadas Cita con resumen
Afdhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian M, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, for the ION-2 investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93. [Ref.ID 97483]
12. Cita con resumen
Liu C-H, Huang C-F, Liu C-J, Dai C-Y, Liang C-C, Huang J-F, Hung P-H, Tsai H-B, Tsai M-K, Chen S-I, Lin J-W, Yang S-S, Su T-H, Yang H-C, Chen P-J, Chen D-S, Chuang W-L, Yu M-L, Kao J-H. Pegylated Interferon-a2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729-38. [Ref.ID 96651]
13.
Martínez Pascual C, Antón Ródenas G, Ortiz Sánchez ML, Pons Miñano JA. Hemofilia A adquirida secundaria al tratamiento con peginterferón alfa-2a en un paciente con hepatitis crónica por el virus C. Med Clin (Barc) 2013;141:228-9. [Ref.ID 96031]
14.
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierting JM, Gordon SC, Andereson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7. [Ref.ID 95633]
15.
Dushelko G, Burney T. Hepatitis C treatment: interferon free or interferon freer?. Lancet 2013;381:2063-5. [Ref.ID 95631]
16.Tiene citas relacionadas
Drenth JPH. HCV treatment - No more room for interfernologists?. N Engl J Med 2013;368:1931-2. [Ref.ID 95542]
17.Tiene citas relacionadas
Liang TJ, Ghany MG. Drug therapy: current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-17. [Ref.ID 95540]
18.Tiene citas relacionadas Cita con resumen
Lawitz E, Mangia A, Wyles D, Rodríguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87. [Ref.ID 95539]
19.Tiene citas relacionadas Cita con resumen
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodríguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin D, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77. [Ref.ID 95538]
20.Enlace a cita original
Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [Ref.ID 95214]
Seleccionar todas
 
 1 a 20 de 116 siguiente >>